Diagnostic value of presepsin for bacterial infection in cirrhosis: a pilot study by Novelli, S. et al.
Diagnostic Value of Presepsin for Bacterial Infection in Cirrhosis:
A Pilot Study
Simone Novellia,*, Vincenzo Morabitob, Franco Rubertob, Fabiano Binib, Franco Marinozzib,
Francesco Puglieseb, Pasquale Berlocob, and Renzo Pretagostinib
aDepartment of Mechanical and Aerospace Engineering, Sapienza University of Rome, Rome, Italy; and bDepartment of General Surgery
and Organ Transplantation, Sapienza University of Rome, Rome, Italyª 2020 The
access artic
creativecom
230 Park Av
TransplantatABSTRACT
Introduction. Presepsin (or sCD14) has been identified as a protein whose levels increase
specifically in the blood of patients with bacterial infections. In this study, we evaluated the
clinical performance of sCD14 and its usefulness in the early diagnosis of bacterial infec-
tion in decompensated cirrhotic patients.
Materials. Seventy patients were enrolled in this study. The mean age of patients was 49.5
years, and 21 were women and 49 men. The heparinized whole blood for the PATHFAST
test was used in the evaluation of bacterial infection (T0). The test was repeated after 48
hours (T1); at 96 hours (T2); at 144 hours (T3); then at 15 days (T4) to monitor the clinical
responses to therapeutic interventions.
Results. Forty-nine patients tested positive for sCD14. The mean sCD14 level was 1854
1744 pg/mL. Microbiological findings confirmed the presence of bacterial infections within
84  4.8 h from enrollment in all 49 positive patients. Thirty-eight patients were considered
responders to empirical antibiotic therapy with a decrease of presepsin at the different time
points, while an increased level of sCD14 was highlighted in 11 patients. When the test was
performed, 45% of the patients showed no signs or symptoms of bacterial infection. At 30
days of follow-up 43 patients survived, and 6 patients died from septic shock.
Conclusions. The PATHFAST test highlighted the presence of infection in a very short
time (15 minutes), and the presepsin could be considered an early biomarker in patients
with cirrhosis. A greater number of patients are necessary to confirm these data.Simone Novelli and Vincenzo Morbito contributed equally to
this work.
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Simone.novelli@uniroma1.itTHE natural course of chronic liver disease is oftencomplicated by acute episodes of potentially reversible
decompensation, triggered by a precipitating event such as a
bacterial infection. A bacterial infection may be present at
admission, or it may appear during the hospital stay in 30%
to 60% of hospitalized patients [1,2].
Several factors are known to facilitate a bacterial infec-
tion: hepatic disease stage, malnutrition, impairment of the
cutaneo-mucous barrier, associated pathology, upper
gastrointestinal hemorrhage, and invasive maneuvers [3,4].
Infection induces a systemic host response with 3 stages of
severity called sepsis, severe sepsis (when an acute organ
failure occurs), and septic shock (when hypotension does
not respond to adequate fluid resuscitation) with a mortality
rate reaching up to 78% [5e9].Authors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
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Spontaneous bacterial peritonitis (SBP) and urinary infections
are the most frequent infections represented in cirrhotic pa-
tients. Immune defects, mainly acquired but also genetic, and
bacterial translocation are the principal mechanism involved
in the pathogenesis of infection in cirrhosis [10]. In addition,
bacterial translocation from the gut is a well-known source of
life-threatening infection, and the most frequent causative0041-1345/20
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1594 NOVELLI, MORABITO, RUBERTO ET ALorganisms in community-acquired infections are Gram-
negative bacilli, mainly Escherichia coli (60%).
Liver dysfunction is associated with an impaired immune
defense against bacteria, which worsens over time and with
disease progression. Both humoral and cell-mediated im-
munity are depressed.
The innate immune system serves as a first-line defense
mechanism against bacteria and toxins. The main effector
cells of the innate immune system are phagocytic cells, such
as macrophages, neutrophils, and monocytes. The main
cellular components of the innate immune system within the
liver are the Kupffer cells. The liver is extremely important
in innate immunity since Kupffer cells represent 80% to
90% of the tissue macrophages in the human body. In the
presence of cirrhosis, the mechanisms of innate immune
dysfunction are numerous. First, Kupffer cells are bypassed
through multiple intra- and extrahepatic shunts. Second,
decreased liver protein synthesis generates defects in com-
plement production. Third, in cirrhosis, there is evidence for
a dysfunctional and hyporesponsive state of the innate im-
mune system, a phenomenon that is known as immune
paralysis.
Beside this immunodeficient state, in the early phase of
bacterial sepsis, circulating levels of the proinflammatory
cytokines such as tumor necrosis factor alpha and inter-
leukin (IL)-6 are significantly higher in infected patients
with cirrhosis than in those without [11]. This excessive
proinflammatory response is recapitulated ex vivo with the
stimulation of isolated peripheral blood mononuclear cells
or monocytes from patients with cirrhosis by lipopolysac-
charides (LPS), which are a part of the external membrane
of Gram-negative bacteria [12]. This bacteria-induced
“cytokine storm” contributes to sepsis-related organ failure.Diagnosis
Early diagnosis and treatment of infection is pivotal in the
management of patients with decompensated cirrhosis.
Blood culture is frequently used as the gold standard diag-
nostic method for sepsis.
However, it usually takes 3 to 7 days to obtain the results,
and the culture frequently yields low positive results.
Therefore, the general practical medical treatment used for
sepsis is based on the doctor’s own experience (empirical
therapy).
Furthermore, bacterial infections in patients with
cirrhosis can be asymptomatic or pauci-symptomatic and
have to be taken into consideration in any cirrhotic patient
with a sudden impairment of liver function [13]. The prog-
nosis of these patients is mainly dependent on a prompt and
accurate diagnosis [14].
For these reasons, the use of systemic inflammatory
response syndrome (SIRS) or early biomarkers for diagnosis
are used in cirrhotic patients. The application of SIRS is
particularly difficult due to the following findings [15-18]:
reduced baseline polymorphonuclear cell count due tohypersplenism; elevated baseline heart rate due to hyper-
dynamic circulatory syndrome; hyperventilation due to he-
patic encephalopathy; and blunted elevation of body
temperature that is often observed in cirrhotic patients.
SIRS is present in 10% and 30% of decompensated
cirrhotic patients without infection and in 57% to 70% of
infected patients, which suggests that SIRS is not the best
marker of infection in the cirrhotic population.
Concentrations of C-reactive protein (CRP) and pro-
calcitonin (PCT) have been suggested as early markers of
infection. While CRP is produced predominantly by hepa-
tocytes, PCT is produced ubiquitously by thyroidal and
extrathyroidal tissues, including the liver [19]. These 2
acute-phase serum proteins are commonly used as early
markers of infection in the noncirrhotic population with a
significant sensibility [20]. On the other hand, patients with
liver failure could present an attenuated production of
acute-phase proteins, especially CRP, in response to
infection.
In fact, conflicting results exist regarding threshold values
and diagnostic accuracy of CRP and PCT in patients with
cirrhosis. Bota et al [21], in the evaluation on 79 cirrhotic
patients, showed that the serum CRP concentration
(admission 11.2  4.6 vs 13.0  5.8, maximum 13.9  6.4 vs
18.8  7.3 mg/dL) and PCT (admission 1.3  0.9 vs 2.0 
1.4, maximum 3.3  1.8 vs 3.4  2.1 ng/mL) were slightly
lower in infected patients with cirrhosis than in infected
patients without cirrhosis, but the differences were not
statistically significant.
Recently, a new biomarker was introduced. Presepsin,
which is approximately 13 kDa, has been identified as a
protein whose levels increase specifically in the blood of
sepsis patients. Presepsin is thought to be a fragment of
CD14, the lipopolysaccharide-binding protein (LPSeLBP)
complex receptor, and it is produced in response to bacterial
infections.
CD14 also exists in a soluble form (sCD14), a glycopro-
tein that derives from either the protease-mediated mem-
brane CD14 shedding [22,23] or liver synthesis as a type II
acute phase reactant [24]. LBP is a 58-kDa glycoprotein
synthesized in the liver that is released into circulation as a
type I acute-phase reactant [25-27]. Levels of LBP peak in
serum shortly after bacteremia or endotoxemia. Once in the
circulation, LBP forms a complex with LPS that enhances
the binding of LPS with CD14 receptors [28]. Membrane
CD14 is associated with TLR-4, which transduces a signal
from the CD14-bound LPS to the cell nucleus, triggering a
cascade of inflammatory cytokines [29]. Some of these cy-
tokines, specifically IL-1 and IL-6, induce the synthesis of
acute-phase proteins in the liver [30]. Membrane CD14,
sCD14, and LBP thus participate in a complex mechanism
of immune regulation involving both up regulation and
down regulation of the inflammatory process triggered by
LPS.
In a study of 207 patients, Endo et al [31] conducted the
clinical usefulness of presepsin for discriminating between
Table 1. Demographic, Clinical, and Biochemical Characteristics
of Patients With Decompensated Cirrhosis at Admission
Patients (No. 70)
Age (years) 49.5  7.6
Sex (male/female) 49/21
MELD Score 23  3.6
Serum bilirubin (mg/dL) 11  2.1
Serum creatinine (mg/dL) 1.6  1.7
Serum albumin (g/dL) 2.4  0.9
Serum lactate (mmol/L) 2.1  0.7
Arterial ammonia (mg/dL) 114  46.3
PMN count (cells/mm3) 9789  4122
INR 2.1  1.05
mAP (mm Hg) 77  8.9
HR (b/min) 91  3.5
Cause of Cirrhosis
Alcohol 20 (28%)
HCV 29 (42%)
HBV 14 (20%)
DIAGNOSTIC VALUE OF PRESEPSIN 1595bacterial and nonbacterial infections (including systemic
inflammatory response syndrome) by comparing it with PCT
and IL-6. The results showed a higher sensibility and spec-
ificity of CD14s than PCT and IL-6 in asserting the presence
of bacterial infection.
Additionally, the measurement of presepsin concentra-
tions is useful for evaluating the severity of infection and
also for monitoring the clinical responses to therapeutic
interventions [32].
Aim of Study
The first endpoint of the study was the evaluation of the
clinical performance of presepsin and its usefulness in the
early diagnosis of bacterial infections in cirrhotic patients.
The second endpoint was based on an evaluation of anti-
biotic therapy response compared to presepsin levels.
Finally, the outcome of patients at 30 days was evaluated.PBC 7 (10%)
Precipitating Events
Ascites 21 (30%)
Variceal bleeding 18 (26%)
Renal failure 15 (21%)
Suspected bacterial infection 8 (11.5%)
Encephalopathy 8 (11.5%)
Categorical data were summarized as proportions and percentages; contin-
uous data, as mean values and standard deviations, were reported.
Abbreviations: HBV, hepatitis B virus related; HCV, hepatitis C virus related;
HR, heart rate; INR, international normal ratio; mAP, mean arterial pressure;
MELD, Model for End-Stage Liver Disease; PMN, polymorph-nuclear; PBC,
primary biliary cirrhosis.MATERIALS AND METHODS
The study was compliant with the 1975 Declaration of Helsinki as
revised in 2008 and approved by the Ethical Committee of Umberto
I Policlinic of Rome, Italy (ref. no. 3101). Written informed consent
was obtained for all participants.
Patients
Seventy decompensated cirrhotic patients hospitalized at our
University Hospital were enrolled (Table 1). Diagnosis of
cirrhosis was based on liver biopsy, when available, or on obvious
clinical, biochemical, or ultrasonographic and endoscopic fea-
tures. Seven other patients with a diagnosis of hepatic carcinoma
were excluded.
At admission, previous relevant clinical data, such as origin of
liver disease, history of alcohol abuse, ascites, encephalopathy,
gastrointestinal bleeding, acute or chronic renal failure, and coex-
istence of other diseases, were recorded.
The main cause of hospitalization was identified, and basal
clinical and biochemical parameters were assessed to define the
severity of liver disease and renal function. Mean arterial pressure,
heart rate, respiratory rate, and body temperature were measured,
and the presence of systemic inflammatory response syndrome
(SIRS) was investigated [17]. The severity of liver disease was
assessed using the Model for End-Stage Liver Disease (MELD)
score [33]. Renal failure was diagnosed according to international
criteria [34]. Complications of cirrhosis were treated according to
recent guidelines [35].
Diagnosis of Infection: Evaluation of Presepsin
The heparinized whole blood for the PATHFAST Assay System
(PAS) was used in the evaluation of bacterial infection presence at
admission (T0). The test was repeated after 48 hours (T1); at 96
hours (T2); at 144 hours (T3), then at 15 days (T4) to monitor the
clinical responses to therapeutic interventions.
At the same time points, blood and urine cultures and ascetic
fluid cell analysis were performed. In accordance to local epide-
miology, empirical antibiotic therapy (EAT) with beta-lactamase
was administered at (T0) in patients who tested positive for
presepsin.PATHFAST Assay System
The PAS contains magnetic particles coated with mouse monoclonal
antibodies and alkaline phosphatase (ALP)-labeled rabbit polyclonal
antibodies. Presepsin in the specimen binds to the antipresepsin an-
tibodies to forman immunocomplex with theALP-labeled antibodies
and the antibody-coated magnetic particles. After removal of the
unbound ALP-labeled antibodies, a chemiluminescent substrate was
added to the immunocomplex. After a short incubation period, the
luminescence generated by the enzyme reaction was detected to
calculate the concentration of presepsin in the samples. The assay
time was 15 minutes using a sample volume of 100 mL. The entire
procedure was automatically performed on the PATHFAST
analyzer. Heparinized whole blood samples were collected from 25
patients at admission and immediately assayed with the PATHFAST
assay. A value > 377 pg/mL was considered positive.Definitions
Patients were considered to have SIRS when they fulfilled the
criteria established by the most recent international guidelines.
Sepsis was diagnosed in the presence of SIRS and a known or
highly suspected infection. Septic shock was defined as sepsis with
hypotension refractory to intravascular volume loading, associ-
ated with perfusion abnormalities that required the use of
inotropes.
The definition of a multidrug-resistant (MDR) pathogen was
used to describe a methicillin-resistant, an extended-spectrum b-
lactamaseseproducing Gram-negative strain, or any bacterial isolate
resistant to at least 3 classes of antimicrobial agents.
Fig 1. Receiver operator characteristic analysis for a correct
cutoff value.
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recommendations of the Asian Pacific Association for the Study of
the Liver in March 2009.
Statistical Analysis
Categorical data were summarized as proportions and percentages;
continuous data, as mean values and standard deviations, were re-
ported. Statistical analysis was performed using GraphPad InStat
software (GraphPad Software, San Diego, Calif, USA), version
6.0b. To determine differences between groups not normally
distributed, medians were compared using the Mann-Whitney U
test. A P value < .05 was considered significant. The results are
depicted in boxplots.
We performed a Roc analysis in order to determine a cutoff value
for the sepsis (Fig 1). The cutoff value was a sdC14 value greater than
669.5 pg/mL with a specificity of 98.1% and sensitivity of 99.1%.
The area under the curve is 0.98%, standard error of 0.01,
P value of .001, and a positive predictive value and negative pre-
dictive value of 96.08% and 99.5%, respectively.RESULTS
Seventy patients with a diagnosis of decompensated
cirrhosis were evaluated at admission (Table 1). Forty-nine
resulted positive to PATHFAST with a mean presepsin
level of 1854  1744 pg/mL. The mean MELD score was 26
 1.6, and 22 patients (45%) resulted as asymptomatic at
admission.
In these 49 patients, the origin of cirrhosis was alcohol
abuse in 37% of cases, hepatitis C in 39%, hepatitis B in
18%, and primary biliary cirrhosis in 6%.
The main reasons for hospital admission of 49 patients
were as follows: refractory ascites in 14 patients (28.5%),
variceal bleeding in 11 (22.5%), encephalopathy in 8 (16%),
suspected infection in 7 (14%), and renal failure in 9 (19%;
Table 2).
The patients affected by refractory ascites showed a mean
value of presepsin of 1216  319.87 pg/mL; by variceal
bleeding 1036  425.38 pg/mL; by encephalopathy 700 
168.76 pg/mL; by suspected infection 2282  536.06 pg/mL,
and by renal failure for a mean value of 1700  959.21 pg/
mL (Fig 2).
As reported in Fig 3, a significant decrease of sCD14 was
observed at the different time points in response to the
antibiotic therapy and an improvement of clinical status.
Thirty-three (67.5%) patients, highlighting a decrease of
presepsin levels, were considered responders to EAT. Pre-
sepsin level values began to decrease at (T2) and fell below
threshold level at (T3; Fig 4).
However, at (T2), 16 patients (32.5%) who showed an
increase of presepsin levels (Fig 4) were evaluated as no
responders to EAT.
In 4 of these patients, after antibiogram results, a specific
antibiotic therapy was applied, and more time was neces-
sary to lower presepsin levels below threshold levels of 377
pg/mL.
In the other 12 patients, who were still waiting for the
cultures results, a different empirical treatment was sug-
gested with meropenem (2 g/day) and vancomycin (2 g/day).
As shown in Table 3, 5 of these 12 patients had an infection
caused by an MDR bacteria and died during their hospital
stay, showing an increase of presepsin levels at the different
time points.
Microbiological findings confirmed the presence of bac-
terial infections within 84  4.8 hours from enrollment in all
49 patients (Table 3). In 8 patients (12%), with low values of
CD14s (< 500 pg/mL), we obtained a urine culture positive
only. Eleven patients who were hospitalized for refractory
ascites showed a positive ascetic fluid cell analysis. Gram-
negative organisms, particularly Escherichia coli, were iso-
lated more frequently (62%) than Gram-positive ones
(38%) (Fig 5).
No significant correlation (R ¼ 0.402) was found between
CD14s and a MELD score of 49 patients at admission, as
reported in Fig 6.
The negative patients (n ¼ 21) to sCD14 showed either a
negative urine or blood culture. No correlation was found
Table 2. Demographic, Clinical, and Biochemical Characteristics
of Patients Positive to Presepsin
Patients (No. 49)
Age (years) 51.4  4.9
Sex (male/female) 36/13
sCD14 (pg/mL) 1854  1744
MELD Score 26  1.6
Serum bilirubin (mg/dL) 12  2.9
Serum creatinine (mg/dL) 1.7  1.5
Serum albumin (g/dL) 2.2  0.6
Serum lactate (mmol/L) 2.1  0.7
Arterial ammonia (mg/dL) 178  51.5
PMN count (cells/mm3) 10,560  3277
INR 2.2  0.9
mAP (mm Hg) 73  7.2
HR (b/min) 97  2.8
Cause of Cirrhosis
Alcohol 18 (37%)
HCV 19 (39%)
HBV 9 (18%)
PBC 3 (6%)
Precipitating Events
Ascites 14 (28.5%)
Variceal bleeding 11 (22.5%)
Renal failure 9 (19%)
Suspected bacterial infection 7 (14%)
Encephalopathy 8 (16%)
Categorical data were summarized as proportions and percentages;
continuous data, as mean values and standard deviations, were reported.
Abbreviations: HBV, hepatitis B virus related; HCV, hepatitis C virus related;
HR, heart rate; INR, international normal ratio; mAP, mean arterial pressure;
MELD, Model for End-Stage Liver Disease; PBC, primary biliary cirrhosis; PMN,
polymorph-nuclear.
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of follow-up, 43 patients (88%) survived, and 6 died (12%).
DISCUSSIONS
The present study on the use of presepsin as a biomarker for
bacterial infections contains some limitations that merit
considerations. First, it was a single-center study and did not
compare sCD14 with other biomarkers or severity score
systems. Second, the possible risk factors of bacterial in-
fections have not been investigated.
Conversely, bacterial infections are frequent and repre-
sent a relevant issue in cirrhotic patients. Patients with
cirrhosis are immunocompromised and as such are highly
susceptible to dissemination of infections, which can lead to
worsening of hepatic function and the development of se-
vere disease complications; therefore, early diagnosis of
infections remains the goal.
In the present study, we analyzed a new rapidmeasurement
method for whole blood that uses a chemiluminescence
enzyme immunoassay and a new biomarker for bacterial
infection. The PATHFAST assay system demonstrated a
sufficient analytical performance. The sensitivity of the
PATHFAST assay was sufficient to detect the presepsin
concentrations in cirrhotic patients within 15 minutes.
Presepsin could be considered a highly specific marker for
the diagnosis of bacterial infections in comparison to other
sepsis markers because of its mechanism of production by
bacterial phagocytosis. In a multicenter prospective study on
207 patients, Endo et al [31] showed that the area under theFig 2. Scatter plot of mean sCD14
levels evaluated at admission,
divided following the precipitating
events. BI, bacterial infections;
HE, hencephalopathy; RF, renal
failure; VB, variceal bleeding.
Fig 3. Scatter plot of mean sCD14 levels valuated in plasma
samples (49 pts) at different time points. Admission T0; 48h T1;
96h T2; 144h T3; 15 days T4. Statistical analysis was performed
with Mann-Whitney U test. P value < .05 was considered statis-
tically significant.
Fig 4. Scatter plot of mean sCD14 levels valuated in plasma
samples of responders (38 pts) and no responders (11 pts) to
empirical antibiotic therapy at different time points. *P ¼ .002;
yP ¼ .03; no significant differences at T1 and T4. T2: Empirical
antibiotic therapy changed in 11 no responder patients; 48h
T1; 96h T2; 144h T3; 15 days T4. Statistical analysis was per-
formed with Mann-Whitney U test. P value < .05 was considered
statistically significant.
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sepsin, 0.905 for PCT, and 0.825 for IL-6 in patients with
bacterial infectious disease and those with nonbacterial in-
fectious disease.
Presepsin is secreted from granulocytes by infectious
stimuli with a sensitivity of 95.5% for Gram-positive and
88.8% for Gram-negative bacterial infections. In accor-
dance to a study of Shozushima et al [36], no significant
differences in presepsin levels between the Gram-positive
and Gram-negative bacterial infection groups was
observed. On the other hand, Gram-negative bacteria
groups were more represented than gram positive bacteria.
As reported in a paper of Gustot et al [6], the causative
organisms of community-acquired infection are Gram-
negative bacilli in about 60%, Gram-positive cocci in
about 30% to 35%, and mixed in the last 5% to 10%.
In addition, bacterial overgrowth and translocation from
the gastrointestinal tract are important steps in the patho-
genesis of spontaneous bacterial peritonitis (SBP) andTable 3. Mean CD14s VALUEs at Admission, Blood and Urine Cultu
Microbiologica
Pathogens Total Mean sCD14
Escherichia coli 19 (38.7%) 1620  885
Enterococcus 8 (16.3%) 814  99
Staphylococcus aureus 6 (12%) 866  307
Pseudomonas aeruginosa 5 (10%) 2655  765
Klebsiella MDR 4 (8%) 1100  333
Klebsiella 3(6%) 1055  459
Proteus mirabilis 2 (4%) 740  201
Acinetobacter MDR 1(2%) 1635
Survival of patients evaluated at 30th day.
Abbreviation: MDR, multidrug resistance.bacteremia. These processes increase levels of endotoxins
and cytokines that induce the inflammatory response and
can lead to septic shock, multiorgan dysfunction, and death.
Specifically, Escherichia coli, Klebsiella, and other
Enterobacteriaceae most frequently cause infection in pa-
tients with cirrhosis [37] and have been found to be the most
adept at translocating from the gut [38]. Escherichia coli, the
pathogen more relived in this study (37.5%), has been
shown to translocate more efficiently, probably as a result of
a greater ability to adhere to the intestinal mucosa.
An interesting aspect was the presence of 45% of patients
without signs or symptoms of infection at admission. In
these patients, the sCD14 evaluation was important to
highlight the early phase of infection, starting with EAT.
However, a more relevant emerging problem in cirrhotic
patients is the increased prevalence of multidrug-resistant
(MDR) bacteria.
Twelve patients resulted as no responders to EAT, thus 4
patients, hospitalized by alcohol-related cirrhosis with renal
failure or suspected infection as precipitating events, werere Results, and Outcomes of 49 Positive Patients in Respect to
l Findings
Blood Culture
Positive
Urine Culture
Positive Survival of Patients
15 (79%) 4 (21%) 18 (95%)
8 (100%) - 8 (100%)
4 (66%) 2 (33%) 6 (100%)
5 (100%) - 4 (80%)
4 (100%) - 1 (25%)
2 (66%) 1 (33%) 3 (100%)
- 2 (100%) 2 (100%)
1 (100%) - 0
Fig 5. Scatter plots of mean sCD14 levels valuated in plasma
samples of survived (43 pts) and not survived (6 pts) at T4.
DIAGNOSTIC VALUE OF PRESEPSIN 1599affected by Klebsiella MDR. These 4 patients, who died
from septic shock between the 15th and 24th day, showed
presepsin values lower at admission than other surviving
patients, highlighting no correlation between presepsin
values and kind of pathogen.
SBP is the most common infection in cirrhotic patients
with ascites and represents one of the most studied infections
because of the severe prognosis and high rate of recurrence.
In our cohort, the ascites represented a cause of hospitali-
zation in 21/70 patients (30%); 11 patients showed SPB.
Ten patients (90%) with SPB resulted as responders to
EAT with a decrease of presepsin levels corresponding to a
decrease of ascitic neutrophil count to < 250/mm3 and
sterile cultures of ascitic fluid to (T3).
In total, 38 were considered responders to EAT, showing
presepsin level reduction and negative cultures at (T3).
In 8 responders with a diagnosis of SIRS, we highlighted
positive urine cultures only. Shozushima et al [36] showedFig 6. Scatter plot of linear regression of correlation between
sCD14 levels and MELD score of 49 patients at admission.
MELD, Model for End-Stage Liver Disease.that Cd14s levels were significantly lower in SIRS (343 
130 pg/mL) not complicated by infection than patients with
sepsis, or severe sepsis, suggesting that presepsin increases
specifically in infections.
Maybe, the cutoff of 377 pg/mL, as indicated by manu-
facturers, is too low to underline the presence of systemic
infection and start an empirical antibiotic therapy.
The antimicrobial treatment failure is relevant in cirrhotic
patients but extremely difficult to estimate. A meta-analysis
[39] of 5 studies performed in patients with gastrointestinal
bleeding has shown that antibiotic prophylaxis significantly
decreased both the incidence of severe infections (SBP or
septicemia) and mortality.
On the other hand, given the inevitable risk of developing
resistant organisms, the use of prophylactic antibiotics must
be rigorously restricted. Causes include altered pharmaco-
kinetics due to chronic liver failure and portal hypertension,
which may alter absorption and distribution of orally
administered drugs, expansion of the extracellular fluid
compartment due to low serum albumin, and ascites that
may increase the volume of distribution of hydrophilic an-
timicrobials, whereas reduced first-pass metabolism or total
hepatic biotransformation may increase exposure to and
decrease clearance of lipophilic antimicrobials [40-44].
Finally, at the 30th day of follow-up, 88% of patients with
infection survived, while 12% died. As reported in 2 Italian
studies, the in-hospital mortality in patients with cirrhosis
was 16% to 19% among those with infections (presence of
MDR bacteria was not reported) and 7% to 10% among
those without, respectively [14,18].
CONCLUSIONS
Bacterial infection and sepsis are highly detrimental in
cirrhosis and are frequently caused by immune paralysis of
patients and a resistance to pathogens.
The identification of an early specific biomarker is
fundamental to start an antibiotic treatment with the intent
to stop the sepsis cascade. The PATHFAST Assay System
seemed to be an early indicator of bacterial infection,
evaluating the sCD14 levels. It is fast (15 minutes) and can
be used as a guide either to start antibiotic therapy in the
absence of severe symptoms or to check the success of
antibiotic therapy.
In contrast to blood cultures, presepsinmeasurement can be
performed quickly and easily, not only in laboratories but also
in wards and intensive care units. This retrospective study
needed a bigger number of patients to confirm these results.
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